Epivir hbv glaxosmithkline

Epivir-HBV was discovered by BioChem Pharma and licensed to Glaxo Wellcome in 1990. Under the terms of a license agreement, BioChem Pharma will 1 infection because the lamivudine dosage in EPIVIR-HBV is subtherapeutic and GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or

Epivir HBV Oral tablet 100mg Drug Medication Dosage information. Learn about the Epivir HBV 100mg Tablet GlaxoSmithKline Group of Companies

Epivir-HBV. Bridges to Access. Provided by: GlaxoSmithKline. PO Box 29038. Phoenix, AZ 85038-9038. TEL: 866-728-4368. ALT PHONE: FAX: 1-855-474- 3063 EPIVIR-HBV (lamivudine - solutionoral). Manufacturer: GLAXOSMITHKLINE Approval date: December 8, 1998. Strength(s): 5MGML Epivir-HBV (Lamivudine), Inhibits viral DNA polymerase, GlaxoSmithKline, Philadelphia, PA, FDA Approved 1998. Hepsera (Adefovir Dipivoxil), Inhibits viral


Under agreement, BioChem Pharma will receive royalties from Glaxo Wellcome on sales of lamivudine for use in both HIVAIDS (3TCEpivirCombivir) and HBV Lamivudine (3TC). Trade Name. Zeffix, Epivir-HBV Epivir-HBV US Prescribing Information, GlaxoSmithKline, January 2011. 1. Pereira AS, Kashuba AD,

3 Mar 2014 State of Florida DOH Central Pharmacy: EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with It is marketed by GlaxoSmithKline with the brand names Zeffix, Heptovir, Epivir, and Epivir-HBV. Lamivudine has been used for treatment of chronic hepatitis B at